

Class	Generic Name	Label Name	Status	Limitations
<b>ANGIOTENSIN II RECEPTOR NTAGONISTS / DIRECT RENIN INHIBITORS / COMBINATION PRODUCTS</b>				
<b>ANGIOTENSIN II RECEPTOR ANTAG &amp; CALCIUM CHANNEL BLOCKER COMB</b>	<b>AMLODIPINE BESYLATE/ OLMESARTAN MEDOXOMIL</b>	<b>AZOR</b>	<b>EA</b>	<b>Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor, and must have a history of dihydropyridine calcium channel blocker and/or angiotensin receptor blocker (ARB) therapy.</b>
	<b>AMLODIPINE BESYLATE/ VALSARTAN</b>	<b>EXFORGE</b>	<b>EA</b>	<b>Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor, and must have a history of dihydropyridine calcium channel blocker and/or angiotensin receptor blocker (ARB) therapy.</b>
	<b>TELMISARTAN/ AMLODIPINE</b>	<b>TWYNSTA</b>	<b>EA</b>	<b>Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor, and must have a history of dihydropyridine calcium channel blocker and/or angiotensin receptor blocker (ARB) therapy.</b>
<b>ANGIOTENSIN II RECEPTOR ANTAGONISTS</b>	<b>AZILSARTAN MEDOXOMIL</b>	<b>EDARBI</b>	<b>PA</b>	<b>Reviewed for medical necessity per compendia, labeling, and efficacy in comparison to less costly alternatives.</b>
	<b>CANDESARTAN CILEXETIL</b>	<b>ATACAND</b>	<b>EA</b>	<b>Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.</b>
	<b>EPROSARTAN MESYLATE</b>	<b>TEVETEN</b>	<b>EA</b>	<b>Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.</b>
		<b>EPROSARTAN MESYLATE</b>	<b>EA</b>	<b>Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.</b>
	<b>IRBESARTAN</b>	<b>AVAPRO</b>	<b>EA</b>	<b>Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.</b>

Class	Generic Name	Label Name	Status	Limitations
<b>ANGIOTENSIN II RECEPTOR NTAGONISTS / DIRECT RENIN INHIBITORS / COMBINATION PRODUCTS CONTINUED</b>				
<b>ANGIOTENSIN II RECEPTOR ANTAGONISTS (CONTINUED)</b>	<b>LOSARTAN POTASSIUM</b>	<b>COZAAR</b>	EA	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.
		<b>LOSARTAN POTASSIUM</b>	EA	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.
	<b>OLMESARTAN MEDOXOMIL</b>	<b>BENICAR</b>	EA	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.
	<b>TELMISARTAN</b>	<b>MICARDIS</b>	EA	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.
	<b>VALSARTAN</b>	<b>DIOVAN</b>	EA	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.
<b>ANGIOTENSIN II RECEPTOR ANTAGONISTS &amp; THIAZIDES</b>	<b>AZILSARTAN MEDOXOMIL/ CHLORTHALIDONE</b>	<b>EDARBYCLOR</b>	PA	Reviewed for medical necessity per compendia, labeling, and efficacy in comparison to less costly alternatives.
	<b>CANDESARTAN CILEXETIL/ HCTZ</b>	<b>ATACAND HCT</b>	EA	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.
	<b>EPROSARTAN MESYLATE/ HCTZ</b>	<b>TEVETEN HCT</b>	EA	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.
	<b>IRBESARTAN/ HCTZ</b>	<b>AVALIDE</b>	EA	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.

Class	Generic Name	Label Name	Status	Limitations
<b>ANGIOTENSIN II RECEPTOR NTAGONISTS / DIRECT RENIN INHIBITORS / COMBINATION PRODUCTS CONTINUED</b>				
<b>ANGIOTENSIN II RECEPTOR ANTAGONISTS &amp; THIAZIDES (CONTINUED)</b>	<b>LOSARTAN POTASSIUM / HCTZ</b>	<b>LOSARTAN POTASSIUM/ HCTZ</b>	EA	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.
		<b>HYZAAR</b>	EA	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.
	<b>OLMESARTAN MEDOXOMIL/ HCTZ</b>	<b>BENICAR HCT</b>	EA	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.
	<b>TELMISARTAN/ HCTZ</b>	<b>MICARDIS HCT</b>	EA	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.
	<b>VALSARTAN/ HCTZ</b>	<b>DIOVAN HCT</b>	EA	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.
<b>ANGIOTENSIN II RECEPTOR ANTAGONISTS - CALCIUM CHANNEL BLOCKER - THIAZIDES</b>	<b>AMLODIPINE/ VALSARTAN/ HCTZ</b>	<b>EXFORGE HCT</b>	EA	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.
	<b>OLMESARTAN MEDOXOMIL/ AMLODIPINE/ HCTZ</b>	<b>TRIBENZOR</b>	EA	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor, and must have a history of dihydropyridine calcium channel blocker and/or angiotensin receptor blocker (ARB) therapy.
<b>DIRECT RENIN INHIBITORS</b>	<b>ALISKIREN FUMARATE TABS</b>	<b>TEKTURN</b>	PA	Reviewed for medical necessity per compendia, labeling, and efficacy in comparison to less costly alternatives.
<b>DIRECT RENIN INHIBITORS &amp; ANGIOTENSIN II RECEPTOR ANTAG</b>	<b>ALISKIREN/ VALSARTAN</b>	<b>VALTURN</b>	PA	Reviewed for medical necessity per compendia, labeling, and efficacy in comparison to less costly alternatives.
<b>DIRECT RENIN INHIBITORS &amp; CALCIUM CHANNEL BLOCKER COMB</b>	<b>ALISKIREN/ AMLODIPINE</b>	<b>TEKAMLO</b>	PA	Reviewed for medical necessity per compendia, labeling, and efficacy in comparison to less costly alternatives.
<b>DIRECT RENIN INHIBITORS &amp; THIAZIDE/THIAZIDE-LIKE COMB</b>	<b>ALISKIREN/ HCTZ</b>	<b>TEKTURN HCT</b>	PA	Reviewed for medical necessity per compendia, labeling, and efficacy in comparison to less costly alternatives.
<b>DIRECT RENIN INHIBITORS-CA CHANNEL BLOCKER-THIAZIDE COMB</b>	<b>ALISKIREN/ AMLODIPINE/ HCTZ</b>	<b>AMTURNIDE</b>	PA	Reviewed for medical necessity per compendia, labeling, and efficacy in comparison to less costly alternatives.

Drug Utilization Review Board Meeting May 23, 2012  
Current Medicaid Status and Restrictions by Drug and Class

Class	Generic Name	Label Name	Status	Limitations
<b>TESTOSTERONE TOPICAL AGENTS</b>				
<b>ANDROGENS -TOPICAL</b>	TESTOSTERONE SOLN	AXIRON	PA	Reviewed for medical necessity per compendia, labeling, and efficacy in comparison to less costly alternatives.
	TESTOSTERONE GEL	ANDROGEL	C	COVERED FOR MALES ONLY
	TESTOSTERONE GEL	TESTIM	C	COVERED FOR MALES ONLY
	TESTOSTERONE GEL	ANDROGEL PUMP	PA	Reviewed for medical necessity per compendia, labeling, and efficacy in comparison to less costly alternatives.
	TESTOSTERONE GEL	FORTESTA	PA	Reviewed for medical necessity per compendia, labeling, and efficacy in comparison to less costly alternatives.
	TESTOSTERONE MISC	STRIANT	C	
	TESTOSTERONE PT24	ANDRODERM	C	COVERED FOR MALES ONLY
	TESTOSTERONE PLLT	TESTOPEL	C	
<b>HISTAMINE-2 RECEPTOR BLOCKERS</b>				
<b>H-2 ANTAGONISTS</b>	CIMETIDINE	ALL FORMS	NP	MUST HAVE TRIED AND FAILED OR BE INTOLERANT TO GENERIC RANITIDINE
	RANITIDINE HCL	ALL GENERIC AND BRANDED GENERIC FORMS	C	
		ZANTAC	NP	MUST HAVE TRIED AND FAILED OR BE INTOLERANT TO GENERIC RANITIDINE
	FAMOTIDINE	ALL FORMS	NP	MUST HAVE TRIED AND FAILED OR BE INTOLERANT TO GENERIC RANITIDINE
	NIZATIDINE CAPS	ALL FORMS	NP	MUST HAVE TRIED AND FAILED OR BE INTOLERANT TO GENERIC RANITIDINE
<b>PRENATAL VITAMINS</b>				
<b>PRENATAL VITAMINS - DHA FORMULATIONS</b>	ALL FORMULATIONS		C	COVERED FOR FEMALES ONLY - LIMITED TO AGES 10-40
<b>PRENATAL VITAMINS - NON DHA FORMULATIONS</b>	ALL FORMULATIONS		C	COVERED FOR FEMALES ONLY - LIMITED TO AGES 10-40